Fibrosis susceptibility gene and uses thereof

a fibrosis susceptibility and gene technology, applied in the field of genetics and medicine, can solve the problems of inability to identify a good marker allowing to predict and follow the progression of hepatic fibrosis in schistosome infected subjects, and inability to afford a global assessment of hepatic fibrosis

Inactive Publication Date: 2016-08-11
UNIV DAIX MARSEILLE +1
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

Enables early detection and monitoring of fibrosis, potentially halting and reversing the fibrotic process, reducing morbidity and mortality associated with hepatic fibrosis and cirrhosis.

Problems solved by technology

There is no good marker allowing to predict and follow hepatic fibrosis progression in Schistosome infected subjects.
Liver biopsy is an invasive and costly procedure, and samples only a small portion of the liver.
Thus it cannot afford a global assessment of hepatic fibrosis, and is subject to sampling variation and inter- and intra-observer error.
Noninvasive tests (i.e., serologic markers, elastometry, ultrasound analysis) are also used but are not yet ready for routine clinical use.
However, when looking at patients individually, these markers could not reliably differentiate between the various stages of fibrosis.
However, the individual stages of fibrosis are not distinguishable using this algorithm.
The limitation of these serum markers is the possibility of false positives when there is highly active hepatic inflammation.
However, the limitations of this technique are associated with attenuation of elastic waves in fluid or adipose tissue, which would impair assessment of fibrosis in patients.
In addition, Fibroscan is an extremely expensive instrument.
However, no efficient method exists to prognose the fibrosis progression and the treatment efficiency.
Treatments aimed at reversing the fibrosis are usually too toxic for long-term use (i.e., corticosteroids, penicillamine) or have no proven efficacy (i.e., colchicine).
In conclusion, efficient and well-tolerated antifibrotic drugs are currently lacking and current treatment of fibrosis is limited to withdrawal of the noxious agent.
However, the genetic factors that control the human fibrosis susceptibility were not identified as well as their effect on fibrosis progression.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Fibrosis susceptibility gene and uses thereof
  • Fibrosis susceptibility gene and uses thereof
  • Fibrosis susceptibility gene and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

example 1

Association Between SNPs in the CTGF Gene Locus with Severe Hepatic Fibrosis (HF) in Two Chinese Populations' Samples

[0095]Data are provided for two independent Chinese samples (fishermen and farmers living in region endemic for S. japonicum). Disease phenotype included advanced hepatic fibrosis (fishermen) as described in Materials and Methods, or ascites and previous bleedings (farmers).

[0096]Association between genotypes and hepatic fibrosis (HF) phenotypes (described in Material and Methods) have been tested first using univariate analysis (upper part of the Table 4) and second by multivariate analysis (lower part of the Table 4) including SNPs or alterations rs12526196, rs1931002, rs3037970 and rs9402373 that showed the strongest associations when tested again SNPs from the same bin. Bins are correlation (r2>0.5) groups, genotype is the aggravating genotype, OR=Odd ratios, CI=Confidence interval of OR.

[0097]Fisherman sample: n=300, 99 cases and 201 controls; covariates: number ...

example 2

Association Between SNPs in the CTGF Gene Locus with Severe Hepatic Fibrosis (HF) in Sudaneses and Brazilians Infected with Schistosoma Mansoni

[0105]The two principal schistosome strains that cause HF are S. japonicum in Asia, and S. mansoni in Africa and in South America. We have investigated whether HF in S. mansoni endemic region of Sudan and Brazil was also affected by CTGF allelic variants. CTGF polymorphisms that were associated with HF in Chinese fishermen (Table 4) were genotyped in both samples. The phenotypes were either severe HF associated with portal hypertension in Sudanese or significant secondary portal branch thickening in Brazilians who were much less affected than Sudanese since transmission was lower in the Brazilians than in the Sudanese sample.

[0106]Associations between genotypes and HF phenotypes (described in Materials and Methods) have been tested first using univariate analysis (upper part of Table 5) and second by multivariate analysis (lower part of Tabl...

example 3

Association Between SNPs in the CTGF Gene Locus with Hepatic Fibrosis (HF) in HCV Infected Subjects

[0118]Analysis of CTGF Genetic Variants in French Subjects Infected with HCV.

[0119]Example 1 describes SNP correlation bins (r2>0.8) in the CTGF encoding gene in a sample of Chinese population. These were defined over the entire gene and 10 Kb of the 3′ and 5′ flanking region. Only SNPs with a minor allele frequency>20% had been analyzed. There were seven bins of which four (groups II, III, IV and VI) showed some association with hepatic fibrosis caused by schistosome eggs in Chinese fishermen infected by Schistosoma japonicum. In Example 3, the inventors genotyped two SNPs in each of these four bins and an additional SNP rs9399005 (that showed suggestive associations with schistosomal fibrosis) in a French sample infected with HCV and determined whether any of them were associated with advanced hepatic fibrosis. They found evidence for association in bins III and VI but not in bins II...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention discloses the identification of a fibrosis susceptibility gene locus, the CTGF gene locus, which can be used for detecting predisposition to, diagnosis and prognosis of fibrosis as well as for the screening of therapeutically active drugs. The invention resides, in particular, in a method which comprises detecting in a sample from the subject the presence of an alteration in the CTGF gene locus, the presence of said alteration being indicative of the presence or predisposition to fibrosis.

Description

FIELD OF THE INVENTION[0001]The present invention relates generally to the fields of genetics and medicine. The present invention discloses in particular the identification of a human fibrosis susceptibility gene, which can be used for the diagnosis or prognosis of fibrosis or for the detection of predisposition to fibrosis, occurring in hepatic diseases, in cirrhosis, cutaneous keloid, obesity and any fibrotic disease. The invention more particularly discloses certain alleles of the CTGF gene on chromosome 6 related to susceptibility to fibrosis and representing novel targets for the screening of therapeutically active drugs. The present invention relates more specifically to particular mutations in the CTGF gene and expression products, as well as to diagnostic tools and kits based on these mutations. The invention can be also used for the prevention and / or treatment of fibrosis occurring in all the fibrotic human diseases.BACKGROUND OF THE INVENTION[0002]Fibrosis is an excessive ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & AuthorityApplications(United States)
IPC IPC(8): C12Q1/68
CPCC12Q1/6883C12Q2600/156C12Q2600/118C12Q2600/172C12Q2600/136Y02A50/30G01N33/56983
InventorDESSEIN, ALAINARNAUD, VIOLAINECHEVILLARD, CHRISTOPHE
OwnerUNIV DAIX MARSEILLE